Page 152 - 80 guidelines for the treatment of malaria_opt

nd
Guidelines for the treatment of malaria – 2 edition edition
Guidelines for the treatment of malaria – 2 nd
importance CRITICAL IMPORTANT IMPORTANT IMPORTANT IMPORTANT

Quality VERY LOW VERY LOW VERY LOW
LOW –

Absolute Not estimable 1 more per 1000 (from 11 fewer to 80 more) 114 fewer per 1000 (from 63 to 118 fewer) Not estimable –

effect Relative risk (95% CI) Not estimable RR 1.08 (0.15–59) RR 0.03 (0–0.47) Not estimable –
Is AS+MQ superior to AQ+SP for treating uncomplicated P. falciparum malaria in Africa?
summary of findings no. of patients AQ + SP AS + MQ 0/154 0/142 (0%) (0%) 2/156 2/144 (1.3%) (1.4%) 19/161 0/145 (11.8%) (0%) 0/161 0/145 (0%) (0%) – –

considerations

Other None None None None –

Imprecision Very serious 6 Very serious 7 No serious imprecision 8 Very serious 9 –

Indirectness Serious 4,5 Serious 4,5 Serious 4,5 Serious 4,5 –

Inconsistency Not applicable Not applicable Not applicable Not applicable

Limitations Serious 3 Serious 3 Serious 3 Serious 3 –

GRADE Table A7.1.2 Quality assessment Design EFFICACy: total failure day 28 PCR adjusted 1 Randomized trial 2 EFFICACy: total failure day 28 PCR unadjusted Randomized trial 2 TRANSMISSION POTENTIAL: gametocyte carriage day 7 Randomized trial 2 HARMS: serious adverse events (including deaths) Randomized trial HARMS: early vomiting

138 No. of studies 1 1 1 1 0